This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Sep;22(9):1562-3.

doi: 10.1038/mt.2014.147.

"Darwinian" tumor-suppression model unsupported in clinical experience

Waseem Qasim¹, Hubert B Gaspar, Adrian J Thrasher

Affiliations

PMID: 25186557
PMCID: PMC4435491
DOI: 10.1038/mt.2014.147

Comment

"Darwinian" tumor-suppression model unsupported in clinical experience

Waseem Qasim et al. Mol Ther. 2014 Sep.

. 2014 Sep;22(9):1562-3.

doi: 10.1038/mt.2014.147.

Authors

Waseem Qasim¹, Hubert B Gaspar, Adrian J Thrasher

Affiliation

¹ Molecular and Cellular Immunology Unit, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, London, UK.

PMID: 25186557
PMCID: PMC4435491
DOI: 10.1038/mt.2014.147

No abstract available

PubMed Disclaimer

Figures

Figure 1
”Darwinian” tumor suppression model in mice. (a) T cells develop in the thymus from progenitor cells. The thymus is continuously supplied with progenitor cells from the bone marrow, which replace thymus-resident progenitor cells. Martins et al. demonstrated that competition between these cells leads to the death of the thymus-resident progenitors in mice. (b) The authors also reported that an absence of competition, when the supply of bone marrow progenitors is blocked, leads to uncontrolled self-renewal of thymus-resident progenitors and T-cell development, such that tumors form. Reprinted with permission from ref. .

See this image and copyright information in PMC

Comment on

Cell competition is a tumour suppressor mechanism in the thymus.
Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V, Lasitschka F, Mastitsky SE, Brors B, Hielscher T, Fehling HJ, Rodewald HR. Martins VC, et al. Nature. 2014 May 22;509(7501):465-70. doi: 10.1038/nature13317. Epub 2014 May 14. Nature. 2014. PMID: 24828041
Cancer: Darwinian tumour suppression.
Moreno E. Moreno E. Nature. 2014 May 22;509(7501):435-6. doi: 10.1038/nature13337. Epub 2014 May 14. Nature. 2014. PMID: 24828043 No abstract available.

Similar articles

Cancer: Darwinian tumour suppression.
Moreno E. Moreno E. Nature. 2014 May 22;509(7501):435-6. doi: 10.1038/nature13337. Epub 2014 May 14. Nature. 2014. PMID: 24828043 No abstract available.
Leukaemia: competition can be a good thing.
Seton-Rogers S. Seton-Rogers S. Nat Rev Cancer. 2014 Jun;14(6):381. doi: 10.1038/nrc3752. Nat Rev Cancer. 2014. PMID: 24854070 No abstract available.
Cell competition is a tumour suppressor mechanism in the thymus.
Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V, Lasitschka F, Mastitsky SE, Brors B, Hielscher T, Fehling HJ, Rodewald HR. Martins VC, et al. Nature. 2014 May 22;509(7501):465-70. doi: 10.1038/nature13317. Epub 2014 May 14. Nature. 2014. PMID: 24828041
Regulation of T-cell progenitor survival and cell-cycle entry by the pre-T-cell receptor.
Aifantis I, Mandal M, Sawai K, Ferrando A, Vilimas T. Aifantis I, et al. Immunol Rev. 2006 Feb;209:159-69. doi: 10.1111/j.0105-2896.2006.00343.x. Immunol Rev. 2006. PMID: 16448541 Review.
The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.
Curtis DJ, McCormack MP. Curtis DJ, et al. Clin Cancer Res. 2010 Dec 1;16(23):5618-23. doi: 10.1158/1078-0432.CCR-10-0440. Epub 2010 Sep 22. Clin Cancer Res. 2010. PMID: 20861166 Review.

See all similar articles

Cited by

Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic stem cell populations?
Ginn SL, McCormack MP, Alexander IE. Ginn SL, et al. Mamm Genome. 2018 Dec;29(11-12):771-776. doi: 10.1007/s00335-018-9780-5. Epub 2018 Sep 4. Mamm Genome. 2018. PMID: 30182300 Review.
Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
Abdulla HD, Alserihi R, Flensburg C, Abeysekera W, Luo MX, Gray DHD, Liu X, Smyth GK, Alexander WS, Majewski IJ, McCormack MP. Abdulla HD, et al. J Exp Med. 2023 Jun 5;220(6):e20212383. doi: 10.1084/jem.20212383. Epub 2023 Mar 15. J Exp Med. 2023. PMID: 36920307 Free PMC article.
Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.
Blanco E, Izotova N, Booth C, Thrasher AJ. Blanco E, et al. Front Immunol. 2020 Nov 27;11:608653. doi: 10.3389/fimmu.2020.608653. eCollection 2020. Front Immunol. 2020. PMID: 33329605 Free PMC article. Review.
Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency.
Ginn SL, Hallwirth CV, Liao SHY, Teber ET, Arthur JW, Wu J, Lee HC, Tay SS, Hu M, Reddel RR, McCormack MP, Thrasher AJ, Cavazzana M, Alexander SI, Alexander IE. Ginn SL, et al. Mol Ther Nucleic Acids. 2017 Mar 17;6:1-14. doi: 10.1016/j.omtn.2016.11.011. Epub 2016 Dec 10. Mol Ther Nucleic Acids. 2017. PMID: 28325276 Free PMC article.

References

1. Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V.et al. (2014Cell competition is a tumour suppressor mechanism in the thymus Nature 509465–470. - PubMed
1. Moreno E. Cancer: Darwinian tumour suppression. Nature. 2014;509:435–436. - PubMed
1. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E.et al. (2008Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 J Clin Invest 1183132–3142. - PMC - PubMed
1. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H.et al. (2008Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients J Clin Invest 1183143–3150. - PMC - PubMed
1. Hassan A, Lee P, Maggina P, Xu JH, Moreira D, Slatter M.et al. (2014Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency J Allergy Clin Immunol 1331660–1666. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information